2019 NCRI Cancer Conference - the UK's largest cancer conference is only a few weeks away. It will take place from Sunday 3 to Tuesday 5 November in Glasgow, UK. Registration for bona fide journalists is free.
The Conference will include the latest cancer research from epidemiology and research in the lab, to treatment trials and quality of life studies.
The media programme will include:
- Research on ovarian cancer could improve clinical guidelines
- Hormones and prostate cancer - what is the link?
- Researchers identify certain gut bacteria that may be involved in causing bowel cancer
- How unusually frequent visits to hospital could reveal who is at risk of myeloma
- Deaths from liver cancer have tripled in past 20 years in England; most deprived at greatest risk
Media can register by email: email@example.com
Every session is open to journalists and registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Full details can be found in the media policy: http://conference.
A media centre with internet connections will be available.
For media queries about the Conference, contact Kerry Noble or Emma Mason, media consultants:
Tel: +44 (0)7446 869 433
More information on the programme is available on the NCRI Cancer Conference website at: https:/
Information on accommodation in Glasgow can be found here:
Reservations are made on a first-come, first-served basis.
The Conference is run by the National Cancer Research Institute, a UK-wide partnership of funders that works to coordinate research related to cancer, to improve the quality and relevance of research, and to accelerate translation of research into clinical practice for the benefit of patients.
NCRI Partners are: Biotechnology and Biological Sciences Research Council (BBSRC); Bloodwise; Brain Tumour Research; Breast Cancer Now; Cancer Research UK; Children with Cancer UK; Department of Health and Social Care; Macmillan Cancer Support; Marie Curie; Medical Research Council (MRC); Northern Ireland Health and Social Care Public Health Agency (Research & Development Department); Pancreatic Cancer Research Fund; Prostate Cancer UK; Scottish Government Health Directorates (Chief Scientist Office); Tenovus Cancer Care; The Wellcome Trust and Welsh Assembly Government (Health and Care Research Wales).
For more information visit http://www.